Increased cross-presentation by dendritic cells and enhanced anti-tumour therapy using the Arp2/3 inhibitor CK666

BACKGROUND: Dendritic cell (DC) vaccines for cancer therapy offer the possibility to let the patient’s own immune system kill cancer cells. However, DC vaccines have shown less efficacy than expected due to failure to induce cancer cell killing and by activating T regulatory cells. METHODS: We teste...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Mariana M. S., D’Aulerio, Roberta, Yong, Tracer, He, Minghui, Baptista, Marisa A. P., Nylén, Susanne, Westerberg, Lisa S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006228/
https://www.ncbi.nlm.nih.gov/pubmed/36631633
http://dx.doi.org/10.1038/s41416-022-02135-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006228/
https://www.ncbi.nlm.nih.gov/pubmed/36631633
http://dx.doi.org/10.1038/s41416-022-02135-4

Ejemplares similares